TABLE 2.
Tumor characteristics of samples giving rise to primary culturesa
| ID | Pathological staging | Source | Histology | % of sarcomatoid | Fuhrman grade | Pretreatment(s) | Resistance to sunitinib in patients |
|---|---|---|---|---|---|---|---|
| T285 | T3aNxMx | Kidney | Clear cell | 0 | 3 | No | |
| T283 | T3aN0Mx | Kidney | Clear cell | 0 | 3 | No | |
| T279 | T3bN0Mx | Vein thrombus | Clear cell | 0 | 3 | No | |
| TG206 | Brain met | Clear cell | NA | No | |||
| TG250 | T2aN0Mx | Kidney | Clear cell | 0 | 3 | No | |
| TG158 | T3aNxMx | Kidney | Clear cell | 5 | 3 | No | |
| T264 | T3bN0Mx | Kidney | Clear cell | 0 | 3 | No | |
| TG144 | T2aN1Mx | Kidney | Clear cell | 0 | 4 | No | |
| TG185 | Kidney | Unclassified | 0 | No | |||
| TG142 | T3aNxMx | Kidney | Clear cell | 0 | 3 | No | |
| TG191 | T3aNxMx | Kidney | Clear cell | 0 | 3 | No | |
| TG143 | T4NxMx | Kidney | Clear cell | 95 | 4 | No | |
| TG180 | Bone met | Clear cell | NA | No | |||
| T249 | T3aN0Mx | Vein thrombus | Clear cell | 0 | 3 | No | |
| TG26 | Adrenal gland | Clear cell | NA | No | |||
| TG169 | T4N1Mx | Kidney | Unclassified | NA | Su | Yes | |
| TG127 | T3aNxMx | Kidney | Clear cell | 0 | 3 | No | Yes* |
| PF22 | Pleural fluid | Clear cell | NA | Su, Ev, Pa, So | Yes | ||
| T258 | T3aN0M1 | Kidney | Clear cell | 15–20 | 4 | No | Yes* |
| T241 | T3aN0M1 | Kidney | Clear cell | 0 | 3 | No | |
| TG194 | T3aNxMx | Kidney | Clear cell | 0 | 3 | No | |
| T239 | T1aNxMx | Kidney | Clear cell | 0 | 2 | No | |
| T256 | Kidney | Prim. Mal. Neo. | 0 | No | |||
| T230 | T2bN1Mx | Kidney | Papillary | 0 | No | ||
| PF114 | Pleural fluid | Clear cell | 0 | Su, Pa | Yes | ||
| TG121 | T1aNxMx | Kidney | Papillary | 0 | No | ||
| T255 | T2aNxMx | Kidney | Chromophobe | 0 | No |
List of samples giving rise to primary cultures. Samples are sorted according to their degree of sensitivity to sunitinib in coculture assays (see Table 3); samples resistant to sunitinib are indicated with boldface characters. Cell lines exhibiting sunitinib resistance in patients were defined as (i) a line derived from a tumor in a patient whose tumor had progressed on sunitinib or (ii) a line derived from a patient subsequently treated with sunitinib (after generation of the line) that exhibited tumor progression within 3 months of treatment onset (indicated with an asterisk). ID, identifier; NA, not available; met, metastasis; Prim. Mal. Neo., primitive malignant neoplasm; Su, sunitinib; Pa, pazopanib; So, sorafenib; Ev, everolimus; No, no pretreatment. When multiple treatments are indicated, they are displayed in the order in which they were administered.